<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/82DF4B15-1E5C-4345-AF7C-E5622AF3684F"><gtr:id>82DF4B15-1E5C-4345-AF7C-E5622AF3684F</gtr:id><gtr:firstName>Oliver</gtr:firstName><gtr:surname>Donnelly</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900324"><gtr:id>AAA7FEE4-DB6F-49AF-B13D-97A784A3D8DC</gtr:id><gtr:title>Combination cytotoxic immune effector cell and oncolytic virus therapy for cancer therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0900324</gtr:grantReference><gtr:abstractText>Certain viruses have been shown, in the laboratory, to be able to kill cancer cells. These viruses are not normally damaging to humans and don?t generally cause significant illnesses. Some cancer cells have lost the ability to eradicate viruses in the way that healthy cells can, so that these viruses can be used to target and selectively kill cancer cells in patients. We are trying to improve the effectiveness of this approach by studying different viruses, and by combining the viruses with cells from the body?s own immune system which themselves can attack cancer. 
Combining cell and viral therapy for cancer is an exciting new approach to cancer therapy. Critically, this research is focused on testing cells and viruses using human reagents, including tumour cells freshly resected from patients; this ensures that our work is of maximum relevance to the disease as seen in patients, and helps rapid translation of our findings into early clinical trials. We?re specifically looking at melanoma; an aggressive form of skin cancer that kills thousands of people, particularly young people, each year, and for which there is little effective treatment. We hope our research will also benefit other cancers too.</gtr:abstractText><gtr:technicalSummary>Oncolytic viruses (OV) are being investigated both for their ability to directly kill cancer cells, and for their role as immunogens, stimulating bystander innate and adaptive anti tumour immune responses. Reovirus (RV) and measles virus (MV) can cause immunogenic tumour cell death, and are already in early clinical trials. Cytotoxic immune effector cells (LAK, NK, CIK, CTL) may potentiate viral therapy, by combining direct cell-mediated killing with an ability to carry (hitchhike) OV, and hand them off to target tumour cells. My aim is to study the combination of immune effector cells and OV as a novel human anti-cancer therapy suitable for clinical translation. I will study the direct innate cytotoxicity of immune effector cells, and direct killing by RV and MV against melanoma, using both cell lines and autologous systems of freshly resected tumour. Combined OV hitchhiked on immune effector cells will then be tested for direct cytotoxicity and activation of anti-tumour immunity. Finally, the effect of cell carriage on protection of OV from neutralising anti-viral antibodies, potentially enhancing in vivo efficacy, will be explored.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>217664</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mayo Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Radiation Oncology Department</gtr:department><gtr:description>Immunogenicity of Radiotherapy</gtr:description><gtr:id>D27C4982-332E-49EB-A6F0-103EB8632CCB</gtr:id><gtr:impact>Ongoing clinical study. Contributions to the 2012 publications listed.</gtr:impact><gtr:outcomeId>fvt3ofL1uM6-1</gtr:outcomeId><gtr:partnerContribution>Prof Vile hosted and funded the preclinical research.
The department of radiation oncology will perform the clinical study</gtr:partnerContribution><gtr:piContribution>During 12 months spent at the Mayo Clinic I worked with Prof Richard Vile on preclinical models of the immune effects of radiotherapy, and with clinicians in the radiation oncology department to develop a translational clinical study of the immune consequences of SBRT for patients with oligometastatic melanoma</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mayo Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Molecular Medicine</gtr:department><gtr:description>Immunogenicity of Radiotherapy</gtr:description><gtr:id>9AFA40B0-941D-4888-9B6B-7BAC7E6257E4</gtr:id><gtr:impact>Ongoing clinical study. Contributions to the 2012 publications listed.</gtr:impact><gtr:outcomeId>fvt3ofL1uM6-2</gtr:outcomeId><gtr:partnerContribution>Prof Vile hosted and funded the preclinical research.
The department of radiation oncology will perform the clinical study</gtr:partnerContribution><gtr:piContribution>During 12 months spent at the Mayo Clinic I worked with Prof Richard Vile on preclinical models of the immune effects of radiotherapy, and with clinicians in the radiation oncology department to develop a translational clinical study of the immune consequences of SBRT for patients with oligometastatic melanoma</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talked to a local group of fundraisers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>5312E5DE-5BD5-4702-8A4E-D256153E85C4</gtr:id><gtr:impact>Spoke to 50 representatives involved in organising fundraising days in 4 local regions to describe the work we do and the need for ongoing funding for medical/cancer reseaerch

N/A</gtr:impact><gtr:outcomeId>JBky33xvk4T</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Yorkshire ACF presentation day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>34009B7D-1318-4ABB-AC15-992588FAB92A</gtr:id><gtr:impact>Annual meeting of Yorkshire academic clinical fellows

Won the prize for the best research and talk</gtr:impact><gtr:outcomeId>i2Cnbf5SLLq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pecha Kucha competition</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>AB3F3D7F-2802-4234-AE1D-A7C0D890D9B9</gtr:id><gtr:impact>Shortlisted for Pecha Kucha competition

Video of presentation being made available online</gtr:impact><gtr:outcomeId>Vq6ARX2DuKa</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Commended for Max Perutz science writing award</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>B19BCDF1-3C75-4A69-9B46-059B4E1B7CEF</gtr:id><gtr:impact>Shortlisted in 2010 and commended in 2011

Description of two projects published online by MRC</gtr:impact><gtr:outcomeId>XMu57SVUnUf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>400</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oncolytic Virus Conference Travel Award</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Mayo Foundation for Medical Education and Research (MFMER)</gtr:fundingOrg><gtr:id>A7AD1723-1C19-4903-B2CD-67511F1AD4A6</gtr:id><gtr:outcomeId>EBU4jfReenr0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ellison Cliffe Travelling Fellowship</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Royal Society of Medicine</gtr:fundingOrg><gtr:id>E20067BD-F36A-42FD-BF38-4808255A6EC0</gtr:id><gtr:outcomeId>c6Jk33gNrjS0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>432AD9DA-DAB8-4ED7-9B77-42228D995BAF</gtr:id><gtr:title>Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c63be9a17585b40fee25e7c34456487"><gtr:id>5c63be9a17585b40fee25e7c34456487</gtr:id><gtr:otherNames>Adair RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_12545_25_22700953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BCAEE92-2EF7-4316-9D66-43B8BAADA91A</gtr:id><gtr:title>The hitchhiker's guide to virotherapy.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c769d87b86307f4b081f05d2d74e417f"><gtr:id>c769d87b86307f4b081f05d2d74e417f</gtr:id><gtr:otherNames>Donnelly O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>pm_12545_25_22964541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9CECB4D-642A-4B9A-B552-5F41CE399E2D</gtr:id><gtr:title>PO-05 Incidental pulmonary emboli in cancer patients - a single centre experience</gtr:title><gtr:parentPublicationTitle>Thrombosis Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c769d87b86307f4b081f05d2d74e417f"><gtr:id>c769d87b86307f4b081f05d2d74e417f</gtr:id><gtr:otherNames>Donnelly O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>GjPGtjdu6RH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>900E628B-17E8-449F-9FBE-B82BFD45F0F2</gtr:id><gtr:title>The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ab908a388a4aaef9413120300f9ebbe"><gtr:id>1ab908a388a4aaef9413120300f9ebbe</gtr:id><gtr:otherNames>Alonso-Camino V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>545c810d419b48.11467186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0099670-F08E-4174-8AA4-49732FDCD67E</gtr:id><gtr:title>Measles virus causes immunogenic cell death in human melanoma.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae243b6f234d856c1d463ec201b4ef6d"><gtr:id>ae243b6f234d856c1d463ec201b4ef6d</gtr:id><gtr:otherNames>Donnelly OG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>pm_12545_25_22170342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>811D9E2E-D224-49B5-9673-522D9B4E786E</gtr:id><gtr:title>Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e40427abb790392b8e0e943c6f2dd6f"><gtr:id>8e40427abb790392b8e0e943c6f2dd6f</gtr:id><gtr:otherNames>Kottke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>545c8172c9e281.39225241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF7B5BA7-58ED-4A46-A6D7-8045BDE9F2EC</gtr:id><gtr:title>Recent clinical experience with oncolytic viruses.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae243b6f234d856c1d463ec201b4ef6d"><gtr:id>ae243b6f234d856c1d463ec201b4ef6d</gtr:id><gtr:otherNames>Donnelly OG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1389-2010</gtr:issn><gtr:outcomeId>UZ2kaHXVDAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8350E75-7310-4865-9637-58511C693AEB</gtr:id><gtr:title>Live viruses to treat cancer.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c769d87b86307f4b081f05d2d74e417f"><gtr:id>c769d87b86307f4b081f05d2d74e417f</gtr:id><gtr:otherNames>Donnelly O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>pm_12545_25_23824333</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900324</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>